Fresenius SE Basic EPS 2016-2024 | FSNUY
Fresenius SE annual/quarterly basic eps history and growth rate from 2016 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Fresenius SE basic eps for the quarter ending June 30, 2024 was $-0.18, a 556.41% decline year-over-year.
- Fresenius SE basic eps for the twelve months ending June 30, 2024 was $-0.53, a 216.16% decline year-over-year.
- Fresenius SE annual basic eps for 2023 was $-0B, a 144.17% decline from 2022.
- Fresenius SE annual basic eps for 2022 was $0.001B, a 33.3% decline from 2021.
- Fresenius SE annual basic eps for 2021 was $0.001B, a 10.3% increase from 2020.
| Fresenius SE Annual Basic EPS |
| 2023 |
$-0.28 |
| 2022 |
$0.64 |
| 2021 |
$0.96 |
| 2020 |
$0.87 |
| 2019 |
$0.95 |
| 2018 |
$1.08 |
| 2017 |
$0.92 |
| 2016 |
$0.81 |
| 2015 |
$0.69 |
| Fresenius SE Quarterly Basic EPS |
| 2024-06-30 |
$-0.18 |
| 2024-03-31 |
$0.13 |
| 2023-12-31 |
$-0.29 |
| 2023-09-30 |
$-0.20 |
| 2023-06-30 |
$0.04 |
| 2023-03-31 |
$0.16 |
| 2022-12-31 |
$0.11 |
| 2022-09-30 |
$0.14 |
| 2022-06-30 |
$0.18 |
| 2022-03-31 |
$0.21 |
| 2021-12-31 |
$0.26 |
| 2021-09-30 |
$0.22 |
| 2021-06-30 |
$0.25 |
| 2021-03-31 |
$0.24 |
| 2020-12-31 |
$0.22 |
| 2020-09-30 |
$0.23 |
| 2020-06-30 |
$0.20 |
| 2020-03-31 |
$0.23 |
| 2019-12-31 |
$0.26 |
| 2019-09-30 |
$0.22 |
| 2019-06-30 |
$0.24 |
| 2019-03-31 |
$0.23 |
| 2018-12-31 |
$0.27 |
| 2018-09-30 |
$0.22 |
| 2018-06-30 |
$0.35 |
| 2018-03-31 |
$0.24 |
| 2017-12-31 |
$0.27 |
| 2017-09-30 |
$0.21 |
| 2017-06-30 |
$0.22 |
| 2017-03-31 |
$0.22 |
| 2016-12-31 |
$0.22 |
| 2016-09-30 |
$0.20 |
| 2016-06-30 |
$0.20 |
| 2016-03-31 |
$0.18 |
| 2015-12-31 |
$0.18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.458B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
